The Experts below are selected from a list of 84 Experts worldwide ranked by ideXlab platform

Gokalp Oner - One of the best experts on this subject based on the ideXlab platform.

  • Transdermal versus oral Estrogen: clinical outcomes in patients undergoing frozen-thawed single blastocyst transfer cycles without GnRHa suppression, a prospective randomized clinical trial
    Journal of Assisted Reproduction and Genetics, 2019
    Co-Authors: Semra Kahraman, Caroline Pirkevi Çetinkaya, Yucel Sahin, Gokalp Oner
    Abstract:

    Purpose To conduct a non-inferiority study to compare the clinical outcomes of transdermal Estrogen Patch and oral Estrogen in patients undergoing frozen-thawed single blastocyst transfer non-donor cycles without GnRHagonist (GnRHa) suppression. Methods A total of 317 women with irregular menses or anovulatory cycle undergoing frozen-thawed embryo transfer (FET) non-donor cycles without GnRHa suppression were involved in a prospective randomized clinical trial between May 2017 and October 2017. The trial was conducted in an ART and Reproductive Genetics Centre within a private hospital. The unit is designated as a teaching center by the Turkish Ministry of Health. Oral or transdermal Estrogen was administered in patients undergoing frozen-thawed single blastocyst transfer. The outcomes of the study were the following: endometrial thickness on the day of progesterone administration, implantation rate, and clinical and viable ongoing pregnancy rates. Results Endometrial thickness and clinical outcomes of oral and transdermal Estrogen administration were equally successful ( p  > 0.05). Conclusion No significant difference was found in endometrial thickness on the day of progesterone administration nor in clinical outcomes between transdermal Estrogen and oral Estrogen in patients undergoing frozen-thawed single blastocyst stage transfer cycles without GnRHa suppression.

  • Transdermal versus oral Estrogen: clinical outcomes in patients undergoing frozen-thawed single blastocyst transfer cycles without GnRHa suppression, a prospective randomized clinical trial.
    Journal of assisted reproduction and genetics, 2018
    Co-Authors: Semra Kahraman, Caroline Pirkevi Çetinkaya, Yucel Sahin, Gokalp Oner
    Abstract:

    To conduct a non-inferiority study to compare the clinical outcomes of transdermal Estrogen Patch and oral Estrogen in patients undergoing frozen-thawed single blastocyst transfer non-donor cycles without GnRHagonist (GnRHa) suppression. A total of 317 women with irregular menses or anovulatory cycle undergoing frozen-thawed embryo transfer (FET) non-donor cycles without GnRHa suppression were involved in a prospective randomized clinical trial between May 2017 and October 2017. The trial was conducted in an ART and Reproductive Genetics Centre within a private hospital. The unit is designated as a teaching center by the Turkish Ministry of Health. Oral or transdermal Estrogen was administered in patients undergoing frozen-thawed single blastocyst transfer. The outcomes of the study were the following: endometrial thickness on the day of progesterone administration, implantation rate, and clinical and viable ongoing pregnancy rates. Endometrial thickness and clinical outcomes of oral and transdermal Estrogen administration were equally successful (p > 0.05). No significant difference was found in endometrial thickness on the day of progesterone administration nor in clinical outcomes between transdermal Estrogen and oral Estrogen in patients undergoing frozen-thawed single blastocyst stage transfer cycles without GnRHa suppression.

Semra Kahraman - One of the best experts on this subject based on the ideXlab platform.

  • Transdermal versus oral Estrogen: clinical outcomes in patients undergoing frozen-thawed single blastocyst transfer cycles without GnRHa suppression, a prospective randomized clinical trial
    Journal of Assisted Reproduction and Genetics, 2019
    Co-Authors: Semra Kahraman, Caroline Pirkevi Çetinkaya, Yucel Sahin, Gokalp Oner
    Abstract:

    Purpose To conduct a non-inferiority study to compare the clinical outcomes of transdermal Estrogen Patch and oral Estrogen in patients undergoing frozen-thawed single blastocyst transfer non-donor cycles without GnRHagonist (GnRHa) suppression. Methods A total of 317 women with irregular menses or anovulatory cycle undergoing frozen-thawed embryo transfer (FET) non-donor cycles without GnRHa suppression were involved in a prospective randomized clinical trial between May 2017 and October 2017. The trial was conducted in an ART and Reproductive Genetics Centre within a private hospital. The unit is designated as a teaching center by the Turkish Ministry of Health. Oral or transdermal Estrogen was administered in patients undergoing frozen-thawed single blastocyst transfer. The outcomes of the study were the following: endometrial thickness on the day of progesterone administration, implantation rate, and clinical and viable ongoing pregnancy rates. Results Endometrial thickness and clinical outcomes of oral and transdermal Estrogen administration were equally successful ( p  > 0.05). Conclusion No significant difference was found in endometrial thickness on the day of progesterone administration nor in clinical outcomes between transdermal Estrogen and oral Estrogen in patients undergoing frozen-thawed single blastocyst stage transfer cycles without GnRHa suppression.

  • Transdermal versus oral Estrogen: clinical outcomes in patients undergoing frozen-thawed single blastocyst transfer cycles without GnRHa suppression, a prospective randomized clinical trial.
    Journal of assisted reproduction and genetics, 2018
    Co-Authors: Semra Kahraman, Caroline Pirkevi Çetinkaya, Yucel Sahin, Gokalp Oner
    Abstract:

    To conduct a non-inferiority study to compare the clinical outcomes of transdermal Estrogen Patch and oral Estrogen in patients undergoing frozen-thawed single blastocyst transfer non-donor cycles without GnRHagonist (GnRHa) suppression. A total of 317 women with irregular menses or anovulatory cycle undergoing frozen-thawed embryo transfer (FET) non-donor cycles without GnRHa suppression were involved in a prospective randomized clinical trial between May 2017 and October 2017. The trial was conducted in an ART and Reproductive Genetics Centre within a private hospital. The unit is designated as a teaching center by the Turkish Ministry of Health. Oral or transdermal Estrogen was administered in patients undergoing frozen-thawed single blastocyst transfer. The outcomes of the study were the following: endometrial thickness on the day of progesterone administration, implantation rate, and clinical and viable ongoing pregnancy rates. Endometrial thickness and clinical outcomes of oral and transdermal Estrogen administration were equally successful (p > 0.05). No significant difference was found in endometrial thickness on the day of progesterone administration nor in clinical outcomes between transdermal Estrogen and oral Estrogen in patients undergoing frozen-thawed single blastocyst stage transfer cycles without GnRHa suppression.

Caroline Pirkevi Çetinkaya - One of the best experts on this subject based on the ideXlab platform.

  • Transdermal versus oral Estrogen: clinical outcomes in patients undergoing frozen-thawed single blastocyst transfer cycles without GnRHa suppression, a prospective randomized clinical trial
    Journal of Assisted Reproduction and Genetics, 2019
    Co-Authors: Semra Kahraman, Caroline Pirkevi Çetinkaya, Yucel Sahin, Gokalp Oner
    Abstract:

    Purpose To conduct a non-inferiority study to compare the clinical outcomes of transdermal Estrogen Patch and oral Estrogen in patients undergoing frozen-thawed single blastocyst transfer non-donor cycles without GnRHagonist (GnRHa) suppression. Methods A total of 317 women with irregular menses or anovulatory cycle undergoing frozen-thawed embryo transfer (FET) non-donor cycles without GnRHa suppression were involved in a prospective randomized clinical trial between May 2017 and October 2017. The trial was conducted in an ART and Reproductive Genetics Centre within a private hospital. The unit is designated as a teaching center by the Turkish Ministry of Health. Oral or transdermal Estrogen was administered in patients undergoing frozen-thawed single blastocyst transfer. The outcomes of the study were the following: endometrial thickness on the day of progesterone administration, implantation rate, and clinical and viable ongoing pregnancy rates. Results Endometrial thickness and clinical outcomes of oral and transdermal Estrogen administration were equally successful ( p  > 0.05). Conclusion No significant difference was found in endometrial thickness on the day of progesterone administration nor in clinical outcomes between transdermal Estrogen and oral Estrogen in patients undergoing frozen-thawed single blastocyst stage transfer cycles without GnRHa suppression.

  • Transdermal versus oral Estrogen: clinical outcomes in patients undergoing frozen-thawed single blastocyst transfer cycles without GnRHa suppression, a prospective randomized clinical trial.
    Journal of assisted reproduction and genetics, 2018
    Co-Authors: Semra Kahraman, Caroline Pirkevi Çetinkaya, Yucel Sahin, Gokalp Oner
    Abstract:

    To conduct a non-inferiority study to compare the clinical outcomes of transdermal Estrogen Patch and oral Estrogen in patients undergoing frozen-thawed single blastocyst transfer non-donor cycles without GnRHagonist (GnRHa) suppression. A total of 317 women with irregular menses or anovulatory cycle undergoing frozen-thawed embryo transfer (FET) non-donor cycles without GnRHa suppression were involved in a prospective randomized clinical trial between May 2017 and October 2017. The trial was conducted in an ART and Reproductive Genetics Centre within a private hospital. The unit is designated as a teaching center by the Turkish Ministry of Health. Oral or transdermal Estrogen was administered in patients undergoing frozen-thawed single blastocyst transfer. The outcomes of the study were the following: endometrial thickness on the day of progesterone administration, implantation rate, and clinical and viable ongoing pregnancy rates. Endometrial thickness and clinical outcomes of oral and transdermal Estrogen administration were equally successful (p > 0.05). No significant difference was found in endometrial thickness on the day of progesterone administration nor in clinical outcomes between transdermal Estrogen and oral Estrogen in patients undergoing frozen-thawed single blastocyst stage transfer cycles without GnRHa suppression.

Yucel Sahin - One of the best experts on this subject based on the ideXlab platform.

  • Transdermal versus oral Estrogen: clinical outcomes in patients undergoing frozen-thawed single blastocyst transfer cycles without GnRHa suppression, a prospective randomized clinical trial
    Journal of Assisted Reproduction and Genetics, 2019
    Co-Authors: Semra Kahraman, Caroline Pirkevi Çetinkaya, Yucel Sahin, Gokalp Oner
    Abstract:

    Purpose To conduct a non-inferiority study to compare the clinical outcomes of transdermal Estrogen Patch and oral Estrogen in patients undergoing frozen-thawed single blastocyst transfer non-donor cycles without GnRHagonist (GnRHa) suppression. Methods A total of 317 women with irregular menses or anovulatory cycle undergoing frozen-thawed embryo transfer (FET) non-donor cycles without GnRHa suppression were involved in a prospective randomized clinical trial between May 2017 and October 2017. The trial was conducted in an ART and Reproductive Genetics Centre within a private hospital. The unit is designated as a teaching center by the Turkish Ministry of Health. Oral or transdermal Estrogen was administered in patients undergoing frozen-thawed single blastocyst transfer. The outcomes of the study were the following: endometrial thickness on the day of progesterone administration, implantation rate, and clinical and viable ongoing pregnancy rates. Results Endometrial thickness and clinical outcomes of oral and transdermal Estrogen administration were equally successful ( p  > 0.05). Conclusion No significant difference was found in endometrial thickness on the day of progesterone administration nor in clinical outcomes between transdermal Estrogen and oral Estrogen in patients undergoing frozen-thawed single blastocyst stage transfer cycles without GnRHa suppression.

  • Transdermal versus oral Estrogen: clinical outcomes in patients undergoing frozen-thawed single blastocyst transfer cycles without GnRHa suppression, a prospective randomized clinical trial.
    Journal of assisted reproduction and genetics, 2018
    Co-Authors: Semra Kahraman, Caroline Pirkevi Çetinkaya, Yucel Sahin, Gokalp Oner
    Abstract:

    To conduct a non-inferiority study to compare the clinical outcomes of transdermal Estrogen Patch and oral Estrogen in patients undergoing frozen-thawed single blastocyst transfer non-donor cycles without GnRHagonist (GnRHa) suppression. A total of 317 women with irregular menses or anovulatory cycle undergoing frozen-thawed embryo transfer (FET) non-donor cycles without GnRHa suppression were involved in a prospective randomized clinical trial between May 2017 and October 2017. The trial was conducted in an ART and Reproductive Genetics Centre within a private hospital. The unit is designated as a teaching center by the Turkish Ministry of Health. Oral or transdermal Estrogen was administered in patients undergoing frozen-thawed single blastocyst transfer. The outcomes of the study were the following: endometrial thickness on the day of progesterone administration, implantation rate, and clinical and viable ongoing pregnancy rates. Endometrial thickness and clinical outcomes of oral and transdermal Estrogen administration were equally successful (p > 0.05). No significant difference was found in endometrial thickness on the day of progesterone administration nor in clinical outcomes between transdermal Estrogen and oral Estrogen in patients undergoing frozen-thawed single blastocyst stage transfer cycles without GnRHa suppression.

Attaya Titivanichpiwong - One of the best experts on this subject based on the ideXlab platform.

  • Effects of Non-Vaginal Route Hormonal Replacement Therapy on Vaginal
    2017
    Co-Authors: Mayuree Jirapinyo, Attaya Titivanichpiwong
    Abstract:

    Objective: To evaluate the Estrogenic effect on the maturation index of hormonal replacement therapy (HRT) in postmenopausal women (PMW). Methods: The maturation indexes (MI) were evaluated based on vaginal cytology which was classified into no, low, moderate and high MI.  Results: There were 70 PMW who were not on HRT evaluated for controls. There were 66%, 23%, 7% and 4% of them had no, low, moderate and high MI. There were 18 PMW who used transdermal Estrogen Patch or gel. It was found that 0%, 66%, 17% and 17% of them had no, low, moderate and high MI. There were 42 PMW who were given oral hormonal tablets. It was found that 7%, 33%, 53% and 7% of them had no, low, moderate and high MI. Conclusion: Hormonal replacement therapy whether via Patch, gel or oral intake resulted in changes in maturation index in postmenopausal women.

  • Effects of Non-Vaginal Route Hormonal Replacement Therapy on Vaginal Maturation Index in Postmenopausal Women
    2008
    Co-Authors: Mayuree Jirapinyo, Attaya Titivanichpiwong
    Abstract:

    Objective: To evaluate the Estrogenic effect on the maturation index of hormonal replacement therapy (HRT) in postmenopausal women (PMW). Methods: The maturation indexes (MI) were evaluated based on vaginal cytology which was classified into no, low, moderate and high MI. Results: There were 70 PMW who were not on HRT evaluated for controls. There were 66%, 23%, 7% and 4% of them had no, low, moderate and high MI. There were 18 PMW who used transdermal Estrogen Patch or gel. It was found that 0%, 66%, 17% and 17% of them had no, low, moderate and high MI. There were 42 PMWs who were given oral hormonal tablets. It was found that 7%, 33%, 53% and 7% of them had no, low, moderate and high MI. Conclusion: Hormonal replacement therapy whether via Patch, gel or oral intake resulted in changes in maturation index in postmenopausal women.